title: Analysis of RCAS1 immunoreactivity within hydatidiform mole cells and decidual cells according to the applied therapeutic strategy: surgery or surgery followed by chemotherapy.
abstract: BACKGROUND
  Trophoblast cells cooperate with both maternal immune cells and decidual cells to help develop the suppressive microenvironment of the endometrium. The maternal immune response against hydatidiform mole depends on this suppressive endometrial profile. Since RCAS1 is one of the molecular factors participating in the development of the suppressive profile of the endometrium we decided to examine the immunoreactivity of the RCAS1 within both the trophoblast and decidual cells during the development of hydatidiform mole.
  
  
  METHODS
  We analyzed the immunoreactivity of RCAS1 on both trophoblast and decidual cells derived from patients who underwent curettage because of hydatidiform mole. These patients were then divided into two subgroups according to whether or not they required chemotherapy after the surgical procedure.
  
  
  RESULTS
  We observed significantly lower immunoreactivity levels of both RCAS1 within the complete molar lesions of the patients on whom surgery alone was performed when compared to the levels found in those for whom surgery was followed by chemotherapy.
  
  
  CONCLUSIONS
  RCAS1 staining may provide information regarding the intensity of the immunosuppressive microenvironment of both the molar lesion and the endometrium. This information can prove significant in determining the clinical course of hydatidiform mole.
authors.affiliation: Departments of Gynecology and Oncology, Lukaszczyk Oncological Center, Bydgoszcz, Poland. mowicher@cyf-kr.edu.pl
authors.forename: Lukasz
authors.initials: L
authors.lastname: Wicherek
authors.forename: Pawel
authors.initials: P
authors.lastname: Basta
authors.forename: Iwona
authors.initials: I
authors.lastname: Wertel
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Kojs
authors.forename: Bogdan
authors.initials: B
authors.lastname: Malkowski
authors.forename: Marek
authors.initials: M
authors.lastname: Grabiec
authors.forename: Milosz
authors.initials: M
authors.lastname: Pietrus
authors.forename: Galazka
authors.initials: G
authors.lastname: Krystyna
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology*; D017024:Chemotherapy, Adjuvant; D003656:Decidua / Q000187:drug effects / Q000276:immunology*; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000188:drug therapy / Q000276:immunology* / Q000601:surgery / Q000628:therapy*; D007150:Immunohistochemistry; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000601:surgery / Q000628:therapy*
chemical_list: D000951:Antigens, Neoplasm; C120762:EBAG9 protein, human